This database contains 68 studies, archived under the term: "adverse"
Click here to filter this large number of results.
One-year safety and tolerability profile of pridopidine in patients with Huntington disease
Squitieri, Ferdinando,
Landwehrmeyer, Bernhard,
Reilmann, Ralf,
Rosser, Anne,
de Yebenes, Justo Garcia,
Prang, Allan,
Ivkovic, Jelena,
Bright, Jeremy,
Rembratt, Åsa
Objective: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease. Methods: Patients received pridopidine 45 mg/day for 4 weeks then pridopidine 90 mg/day for 22 weeks in this 6-month open-label extension (OLE) of the 6-month MermaiHD randomized controlled trial (RCT). Any adverse events (AEs) were recorded. Patients were […]
Postoperative medical complications associated with anesthesia in older adults with dementia
Seitz, Dallas P.,
Gill, Sudeep S.,
Bell, Chaim M.,
Austin, Peter C.,
Gruneir, Andrea,
Anderson, Geoff M.,
Rochon, Paula A.
Objectives: To examine the association between anesthetic technique and postoperative complications in older adults with dementia undergoing hip fracture surgery.; Design: Population-based, retrospective cohort study.; Setting: Ontario, Canada.; Participants: All older adults with dementia who underwent surgery for hip fracture repair in Ontario, Canada, between April 1, 2003 and March 31, 2011.; Measurements: The baseline […]
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease
Sabbagh, Marwan N.,
Agro, Albert,
Bell, Joanne,
Aisen, Paul S,
Schweizer, Edward,
Galasko, Douglas
Objective: To evaluate the safety and tolerability of PF-04494700, an oral inhibitor of receptor for advanced glycation end products, in patients with mild-to-moderate dementia of the Alzheimer type.; Methods: Patients aged 50 years and older who met the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association criteria for Alzheimer […]
Galantamine treatment in outpatients with mild Alzheimer’s disease
Objective: To assess long-term effectiveness of galantamine in community-dwelling persons with mild Alzheimer’s disease.; Methods: Prospective open-label trial including patients with mild AD (NINCDS-ADRDA criteria) treated with galantamine for up to 36 months. Outcome parameters included ADAS-cog/11, Bayer-ADL scale (self- and caregivers’ ratings), 10-item NPI and CGI-change, safety and tolerability measures. Data are presented based […]
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
Porsteinsson, Anton P.,
Drye, Lea T.,
Pollock, Bruce G.,
Devanand, D. P.,
Frangakis, Constantine,
Ismail, Zahinoor,
Marano, Christopher,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Pelton, Gregory,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Shade, David M.,
Weintraub, Daniel,
Yesavage, Jerome,
Lyketsos, Constantine G.
Importance: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.; Objective: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, […]
Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study
Laredo, Leonor,
Vargas, Emilio,
Blasco, Antonio Javier,
Aguilar, Maria Dolores,
Moreno, Alfonso,
Portolés, Antonio
Objectives: To explore the association between use of antipsychotics and risk of cerebrovascular accident (CVA) in individuals with dementia aged 65 and older.; Design: Population-based case-control study.; Setting: UK-based electronic primary care records in the General Practice Research Database (GPRD).; Participants: Individuals with dementia aged 65 and older registered in the database between January 1, […]
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease
Kim, Seong Yoon,
Choi, Seong Hye,
Rollema, Hans,
Schwam, Elias M.,
McRae, Tom,
Dubrava, Sarah,
Jacobsen, Janice
Background: Evidence supports a role of α4β2 receptors in Alzheimer’s disease (AD).; Methods: This Korean, multicenter, double-blind, two-period (6 weeks each), crossover study randomized participants to the order in which they received varenicline (1 mg twice daily) and placebo. Assessments included AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 75, Neuropsychiatric Inventory (NPI), adverse events (AEs) and Columbia-Suicide […]